RNS, PMA, and a Narrow Path to Growth: NeuroPace’s Q1 2026 Earnings

A finance-writer take on NPCE’s first-quarter results, with an eye toward EPS, revenue forecast, and the regulatory road ahead.

Lead summary: growth on the top line, margin nuance, and regulatory momentum

NeuroPace, Inc. (Nasdaq: NPCE) reported its first quarter of 2026 with a clear tilt toward growth in non-GAAP metrics, even as GAAP losses persist. Non-GAAP revenue rose 20.1% year over year to $22.0 million, while GAAP revenue totaled $22.1 million—of which a modest $0.1 million was attributable to DIXI Medical. The company highlighted that RNS System revenue was $21.7 million for the quarter, up 19.5% on a year-over-year basis.

In the optics of earnings per share (EPS) and standard street expectations, NPCE did not publish an EPS figure in this release. The GAAP net loss for the quarter was $6.7 million, versus $6.6 million in Q1 2025, leaving little to cheer in traditional per-share terms. The company did, however, show an improving trend in profitability metrics on a non-GAAP basis, with an adjusted EBITDA loss of $3.3 million for the quarter—improved by $0.8 million versus the prior-year period, excluding DIXI Medical.

Key numbers at a glance

Non-GAAP revenue: $22.0 million, up 20.1% YoY; GAAP revenue: $22.1 million (DIXI Medical contributed $0.1 million).
RNS System revenue: $21.7 million; YoY growth: 19.5%.
GAAP net loss: $(6.7) million; prior-year quarter: $(6.6) million.
Adjusted EBITDA loss (excluding DIXI): $(3.3) million; improvement of $0.8 million vs $(4.1) million in Q1 2025.
FDA progress: completed the NAUTILUS PMA-Smid-cycle review meeting; pipeline and prescribers at all-time highs.
Non-GAAP gross margin: 82.5% (vs 83.6% in Q1 2025, which included a one-time 120 bps benefit from inventory revaluation).
GAAP gross margin: 81.8%.
Non-GAAP operating expenses: $21.5 million; GAAP operating expenses: $23.6 million.
Non-GAAP S&M (excluding DIXI Medical): $11.0 million; prior-year: $9.6 million.
Guidance: full-year 2026 revenue forecast raised to $99–$101 million (from $98–$100 million).
Regulatory/indication outlook: NAUTILUS PMA-S path continues; IGE indication expansion remains a potential tailwind.

Analysis: margins improve but the model remains a work in progress

The quarter shows a familiar pattern for a clinical-stage medical device company: growing top-line revenue on the back of core product sales, paired with persistent non-cash and non-operational adjustments that mask a GAAP loss. The shift to non-GAAP reporting—now including gross margin and operating expenses excluding DIXI Medical and stock-based compensation—aims to illuminate the business’s underlying trajectory and operating leverage. In NeuroPace’s case, the gross margin improvement is modest but meaningful, driven by manufacturing efficiency and a higher average selling price as pricing power broadens.

The combination of $21.7 million in RNS System revenue and a $99–$101 million revenue forecast for 2026 hints at a trajectory where volume growth may outpace costs, but the path to profitability remains anchored to regulatory milestones and indication expansions. The NAUTILUS PMA-S pathway—an FDA regulatory milestone—appears as a potential upside catalyst, particularly if the data package fortifies expectations for IGE indication expansion. Yet, the absence of a reported EPS (earnings per share) figure and the ongoing GAAP losses remind investors that the company remains in a capital-intensive phase.

The company’s commentary signals a disciplined approach to cost structure, with non-GAAP operating expenses of $21.5 million and a non-GAAP gross margin of 82.5% for the quarter. The margin pullbacks from a year earlier are not alarming in isolation, but they do underscore how much of the quarterly profitability in this sector rides on regulatory timing, reimbursable mix, and the pace of adoption by prescribers.

Management tone and strategic context

“First quarter results reflect continued execution against the strategic priorities we outlined earlier this year,” commented Joel Becker, CEO of NeuroPace. “We remain focused on driving disciplined growth in our core RNS business, advancing our product roadmap, and progressing toward potential indication expansion, all while strengthening the operational foundation of the Company. We continue to progress NAUTILUS through the regulatory review process and remain encouraged by the totality of the dataset supporting the IGE indication expansion.”

The quote frames a narrative of steady progress rather than sensational pivots. Expect the company to continue balancing product penetration (RNS system), pipeline development, and regulatory milestones as it aims to convert clinical progress into sustainable cash flow—an outsized question for any company still reporting GAAP losses but inching toward cash-flow considerations via non-GAAP metrics.

Outlook and sector implications

The raised revenue forecast for 2026 signals management’s confidence in continued demand for the RNS System and ongoing contributions from DIXI Medical in the near term, even as it remains a non-GAAP adjustment. In the near term, investors will watch whether the updated guidance translates into a more favorable EPS trajectory under non-GAAP adjustments and whether the NAUTILUS PMA-S progress can unlock broader adoption or new indication revenue streams.

For sector peers—both within neuromodulation and broader implantable devices—the NPCE update reinforces a couple of themes: (1) regulatory timing is a critical catalyst; (2) non-GAAP disclosures that strip out one-off or ancillary contributions (like DIXI Medical) can significantly affect operating metric interpretations; (3) early leads in prescriber engagement and patient pipelines often foreshadow longer-term demand, even if offset by regulatory costs today.

The EEG of the market will likely: a) watch the progress of NAUTILUS PMA-S and subsequent indication expansions for IGE; b) compare gross margin development with peers who may have more mature product lines or larger installed bases; and c) assess whether NPCE’s revenue forecast doors are open to EPS improvement as non-core costs fade or re-accelerate if the regulatory timeline drifts.

Risks and caveats

The company continues to operate at a loss on a GAAP basis. While non-GAAP metrics show improvement, the sustainability of that path depends on continued market adoption of the RNS System, successful execution of the NAUTILUS PMA-S program, and the regulatory environment for additional indications. The absence of an explicit EPS figure in the release means investors must translate the GAAP loss into per-share terms themselves, which can complicate immediate comparisons with consensus estimates. There is also exposure to pricing pressure and reimbursements as the portfolio scales.

Bottom line: a measured quarter with a runway ahead

NeuroPace’s Q1 2026 results present a story of progress that isn’t flashy but carries potential catalysts. The revenue growth, improvements in non-GAAP profitability metrics, and regulatory momentum around NAUTILUS PMA-S create a narrative where the company could convert near-term milestones into longer-term EPS strength—if the stars align with continued RNS adoption and successful indication expansion. For investors tracking NPCE, the next updates will be telling on whether the revenue forecast lift translates into sustained margin leverage and whether any earnings surprise materializes via a per-share figure that aligns with the improved top line.